Stephen L. Hoffman M.D., D.T.M.H., D.Sc. (hon), FASTMH, CAPT, MC, USN (RET)
Chief Executive and Scientific Officer:
Dr. Hoffman has over 25 years of experience building and managing large, successful research and development programs. From 1987-2001 he was Director of the Malaria Program at the Naval Medical Research Center where he built a focused professional team of over 100 individuals in the United States and overseas working on all aspects of malaria research, but especially vaccine development and genomics. Dr. Hoffman and his team were leaders in the effort to sequence the P. falciparum genome and conducted the first studies in the world that showed that DNA vaccines elicited killer T cell responses in humans. In early 2001 Dr. Hoffman retired from the Navy and joined Celera Genomics as Senior Vice President of Biologics to create a program to utilize genomics and proteomics to produce new biopharmaceuticals. He established this program, organized the effort that successfully sequenced the genome of the mosquito responsible for most transmission of malaria in Africa, Anopheles gambiae, and left Celera in August 2002 to found Sanaria. He holds several professorships, and chairs or serves on multiple advisory boards. He is a past president of the American Society of Tropical Medicine and Hygiene, has edited two books on malaria vaccine development, been the author of more than 380 scientific publications, and has numerous patents. He is the most highly cited author in the world for scientific papers on malaria published between 1995 and 2005. He received his B.A. from the University of Pennsylvania, M.D. from Cornell University Medical College, Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine, and did residency training at the University of California, San Diego. He is board certified in Family Practice. In 2004 he was elected to membership in the Institute of Medicine of the National Academies.
Robert C. Thompson
Vice President of Operations:
Joining Sanaria in 2002, Robert C. Thompson has greater than 20 years of operational, administrative and logistics experience in the biotechnology, genomics, analytical instrumentation and semiconductor equipment businesses. From 1998-2002 as director of Operations of Celera Genomics, Bob helped create the world’s largest DNA sequencing and bio-computing operation. From 1992-1998 he served in management positions in Marketing, Sales and Service, Manufacturing and Strategic Planning for the Analytical Instrumentation and the PCR business units of Perkin-Elmer and Applied Biosystems. These roles required the global management and product portfolio planning of instrument manufacturing, the establishment of manufacturing operations in China and Singapore to expand the commercialization of the PCR business, the establishment of a European Distribution Center for Applied Biosystems, including the implementation of global IT and ISO 9000 Quality Systems, and the direction of sales and marketing support services for North American operations. From 1981-1992 he served in both Materials and Manufacturing Management roles in both Perkin-Elmer's Analytical Instrument and Semiconductor Manufacturing Equipment businesses. From 1978-1981 he was Materials Manager for Gelman Sciences. Mr. Thompson received his B.S. in Business and Economics from the University of Bridgeport in 1977.
B. Kim Lee Sim, PhD
Executive Vice President Process Development and Manufacturing:
Dr. Sim, has been associated with Sanaria since its inception. She is also President and Chief Scientific Officer of Protein Potential LLC ( www.proteinpotential.com), a vaccine development company, which she founded in 2003. Dr. Sim did her undergraduate (B.Sc., Honors, First Class) and graduate studies (M.Sc., Ph.D.) at the University of Malaya, Kuala Lumpur, Malaysia. After a post doctoral fellowship in molecular biology at Harvard School of Public Health, she was a research scientist at the Walter Reed Army Institute of Research and an adjunct faculty at the Uniformed Services University of Health Sciences, a research assistant professor at Johns Hopkins School of Public Health, and an Expert at the National Institute of Allergy and Infectious Diseases, NIH. In 1993 Dr. Sim left the NIH to join a start up company, EntreMed Inc, as Research Director of Molecular Biology, and in 1999 she was appointed Vice President Pre-Clinical Research and Development. At EntreMed, Dr. Sim established and managed the development program for anti-angiogenic proteins for the therapy of cancer, and developed the process that led to the cGMP manufacture of tens of kilograms of recombinant Angiostatin and Endostatin, two anti-angiogenic proteins that entered Phase II clinical trials. Dr. Sim has published more than 65 scientific papers, and has 7 issued and more than 15 pending patents.